complete surprise, but given their loss of missing Human Genome last year it makes sense. Acquire the patents before their someone elses. It's small like Human Genome was a couple years ago but they have more than anyone else in terms of drug candidates from patents, and now they can acquire them on the cheap.
My guess, probably a buck a share or a little more. To think shareholders paid 10x that 5yrs ago. HGSI was .90 then.